{"title":"RE: Outcomes after solid organ transplantation in survivors of childhood, adolescent, and young adult cancer: a population-based study.","authors":"Linkun Shen, Sheng Li","doi":"10.1093/jnci/djaf185","DOIUrl":"10.1093/jnci/djaf185","url":null,"abstract":"","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":"1951-1952"},"PeriodicalIF":7.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144637052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jiangrong Wang, Stina Salomonsson, Demet Sönmez, Sara Nordqvist Kleppe, Adina L Feldman, Marcus Sven Andersson, Goran Bencina, Fang Fang, Karin Sundström
{"title":"Mental disorders and socioeconomic outcomes in women with cervical cancer, and their children and co-parents.","authors":"Jiangrong Wang, Stina Salomonsson, Demet Sönmez, Sara Nordqvist Kleppe, Adina L Feldman, Marcus Sven Andersson, Goran Bencina, Fang Fang, Karin Sundström","doi":"10.1093/jnci/djaf129","DOIUrl":"10.1093/jnci/djaf129","url":null,"abstract":"<p><strong>Background: </strong>Cervical cancer often affects women who are in the middle of life and may carry substantial mental and socioeconomic impact also on families. We performed a generation-spanning study to elucidate this burden.</p><p><strong>Methods: </strong>We used nationwide registers during 1991-2018 in Sweden to perform 2 matched cohort studies based on a source population of more than 5 million women. The individual sub-study included 6060 cases of cervical cancer diagnosed during 2006-2018 and 5 population comparators individually matched to each case by age, birth year, and region (n = 30 300). The family sub-study included 9332 cases of cervical cancer diagnosed during 1991-2016 and 45 674 matched population comparators and all their children and co-parents.</p><p><strong>Results: </strong>We found an increased risk for mental disorders in cases compared with comparators, particularly during the first 2 years postdiagnosis (HR = 3.74, 95% CI = 3.45 to 4.06). Socioeconomic status changed negatively in cases after their diagnosis: a decreased income and increased need for financial aid appeared within 2 years, whereas unemployment escalated from 2 years after cancer diagnosis. We further found an increased risk of mental disorders in both children and co-parents of the cases, compared with the children and co-parents of the comparators. Furthermore, we observed negative socioeconomic trajectories in the co-parents and lower educational attainment in the children of the cases, especially if the case had died.</p><p><strong>Conclusions: </strong>Women with cervical cancer, and their close family members, display increased risk of negative mental health and socioeconomic outcomes after diagnosis. The lower educational attainment in children appears particularly worrying.</p>","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":"1825-1835"},"PeriodicalIF":7.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12415958/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144258096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"RE: Influence of endoxifen on mammographic density: results from the KARISMA-Tam trial.","authors":"Tong Zhu, Yinping Jiang, Xudong Zhu","doi":"10.1093/jnci/djaf159","DOIUrl":"10.1093/jnci/djaf159","url":null,"abstract":"","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":"1948-1949"},"PeriodicalIF":7.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144540264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Paul C Nathan, Cindy Lau, Vicky L Ng, Mar Miserachs, Chia Wei Teoh, Melinda Solomon, Anne I Dipchand, Maria Locke, Sumit Gupta
{"title":"Response to Shen and Li.","authors":"Paul C Nathan, Cindy Lau, Vicky L Ng, Mar Miserachs, Chia Wei Teoh, Melinda Solomon, Anne I Dipchand, Maria Locke, Sumit Gupta","doi":"10.1093/jnci/djaf186","DOIUrl":"10.1093/jnci/djaf186","url":null,"abstract":"","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":"1953-1954"},"PeriodicalIF":7.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144637053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
James Yarmolinsky, Matthew A Lee, Evelyn Lau, Ferran Moratalla-Navarro, Emma E Vincent, Ruifang Li-Gao, Patrick C N Rensen, Ko Willems van Dijk, Kostas K Tsilidis, Apiwat Sangphukieo, Elmira Ebrahimi, Jochen Hampe, Loïc Le Marchand, Franzel J B van Duijnhoven, Kala Visvanathan, Michael O Woods, Marcela Guevara, Sabina Sieri, Giovanna Masala, Keren Papier, Shama Virani, Tom Dudding, Abbas Dehghan, Alexander G Smith, Dennis Wang, Victor Moreno, Marc J Gunter, Ioanna Tzoulaki
{"title":"Proteogenomic and observational evidence implicate ANGPTL4 as a potential therapeutic target for colorectal cancer prevention.","authors":"James Yarmolinsky, Matthew A Lee, Evelyn Lau, Ferran Moratalla-Navarro, Emma E Vincent, Ruifang Li-Gao, Patrick C N Rensen, Ko Willems van Dijk, Kostas K Tsilidis, Apiwat Sangphukieo, Elmira Ebrahimi, Jochen Hampe, Loïc Le Marchand, Franzel J B van Duijnhoven, Kala Visvanathan, Michael O Woods, Marcela Guevara, Sabina Sieri, Giovanna Masala, Keren Papier, Shama Virani, Tom Dudding, Abbas Dehghan, Alexander G Smith, Dennis Wang, Victor Moreno, Marc J Gunter, Ioanna Tzoulaki","doi":"10.1093/jnci/djaf137","DOIUrl":"10.1093/jnci/djaf137","url":null,"abstract":"<p><strong>Background: </strong>The role of lipid-perturbing medications in cancer risk is unclear.</p><p><strong>Methods: </strong>We employed cis-Mendelian randomization and colocalization to evaluate the role of 5 lipid-perturbing drug targets (ANGPTL3, ANGPTL4, APOC3, CETP, and PCSK9) in risk of 5 cancers (breast, colorectal, head and neck, ovarian, and prostate). We triangulated findings using pre-diagnostic protein measures in prospective analyses in EPIC (977 colorectal cancer cases, 4080 sub-cohort members) and the UK Biobank (860 colorectal cancer cases, 50 177 controls). To gain mechanistic insight into the role of ANGPTL4 in carcinogenesis, we examined the impact of the ANGPTL4 p. E40K loss-of-function variant on differential gene expression in normal colon tissue in BarcUVa-Seq. Finally, we evaluated the association of colon tumor ANGPTL4 expression with cancer-specific mortality in TCGA.</p><p><strong>Results: </strong>In analysis of 78 473 cases and 107 143 controls, genetically proxied circulating ANGPTL4 inhibition was associated with reduced colorectal cancer risk (ORSD decrease = 0.76, 95% confidence interval [CI] = 0.66 to 0.89, P = 5.52 × 10-4, PPcolocalization = 0.83). This association was replicated using pre-diagnostic circulating ANGPTL4 concentrations in EPIC (hazard ratio [HR]log10 decrease = 0.91, 95% CI = 0.84 to 0.98, P = .01) and the UK Biobank (HRSD decrease = 0.93, 95% CI = 0.86 to 0.99, P = .03). In gene-set enrichment analysis of differential gene expression in 445 colon tissue samples, ANGPTL4 loss-of-function down-regulated several cancer-related biological pathways (PFDR < .05), including those involved in cellular proliferation, epithelial-to-mesenchymal transition, and bile acid metabolism. In analysis of 465 colon cancer patients, lower ANGPTL4 tumor expression was associated with reduced colorectal cancer-specific mortality risk (HRlog2 decrease = 0.66, 95% CI = 0.50 to 0.87, P = 2.92 × 10-3).</p><p><strong>Conclusions: </strong>Our integrative proteogenomic and observational analyses suggest a potential protective role of lower circulating ANGPTL4 concentrations in colorectal cancer risk. These findings support further evaluation of ANGPTL4 as a therapeutic target for colorectal cancer prevention.</p>","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":"1836-1847"},"PeriodicalIF":7.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12415964/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144284379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Success in oncology phase 3 trials: a small P value or patient value.","authors":"Laure-Anne Teuwen, Gregory R Pond, Bishal Gyawali","doi":"10.1093/jnci/djaf183","DOIUrl":"https://doi.org/10.1093/jnci/djaf183","url":null,"abstract":"","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":"117 9","pages":"1761-1763"},"PeriodicalIF":7.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145015426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sarah L Kerns, Paul C Dinh, Patrick O Monahan, Timothy Stump, Chunkit Fung, Howard D Sesso, Darren R Feldman, Robert J Hamilton, David J Vaughn, Robert Huddart, Christian Kollmannsberger, Neil E Martin, Kathryn Nevel, John Kincaid, Lawrence H Einhorn, Lois B Travis
{"title":"Factors associated with longitudinal progression of the cumulative burden of morbidity and overall mortality after cisplatin-based chemotherapy for testicular cancer.","authors":"Sarah L Kerns, Paul C Dinh, Patrick O Monahan, Timothy Stump, Chunkit Fung, Howard D Sesso, Darren R Feldman, Robert J Hamilton, David J Vaughn, Robert Huddart, Christian Kollmannsberger, Neil E Martin, Kathryn Nevel, John Kincaid, Lawrence H Einhorn, Lois B Travis","doi":"10.1093/jnci/djaf014","DOIUrl":"10.1093/jnci/djaf014","url":null,"abstract":"<p><strong>Background: </strong>To comprehensively evaluate the longitudinal progression of cumulative burden of morbidity (CBM) in testicular cancer survivors (TCS) following standard-dose cisplatin-based chemotherapy and the impact of modifiable risk factors on morbidity and early mortality.</p><p><strong>Methods: </strong>Participants completed first-line chemotherapy at or longer than 6 months before baseline assessments with comprehensive questionnaires and physical examinations. Based on follow-up assessments (median: 7 years later), longitudinal progression of adverse health outcomes (AHOs) and CBM score (encompassing AHO number and severity) were examined. Baseline health behaviors and AHOs were evaluated for associations with mortality using mixed-effects parametric proportional-hazards regression to identify modifiable risk factors.</p><p><strong>Results: </strong>Among 616 TCS longitudinally assessed, 23% experienced worsening CBM postchemotherapy (median = 11 years, interquartile range = 7-15). Declines were driven by worsening treatment-related AHOs: tinnitus (29.7%), hearing loss (24.4%), Raynaud's disease (22.6%), neuropathy (18.5%), and neuropathic pain (10.7%). Baseline factors associated with worsening neuropathy included lack of aerobic physical activity (odds ratio [OR] = 1.98, 95% confidence interval [CI] = 1.06 to 3.72), and obesity (OR = 1.85, 95% CI = 1.17 to 2.92). These were also related to worsening neuropathic pain (OR = 2.82, P = .009 and OR = 2.29, P = .023). Twenty-nine deaths occurred among 1830 5-year TCS (4.2% cumulative hazard) (median age = 48 years, range = 22-74). Participants reporting neuropathic pain (hazard ratio [HR] = 3.64, 95% CI = 1.45 to 9.10), no aerobic (HR = 6.56, 95% CI = 2.73 to 15.8), or no low-impact physical activity (HR = 3.96, 95% CI = 1.40 to 11.2) had significantly higher mortality, as did TCS indicating fair (HR = 9.23, 95% CI = 3.08 to 27.8) or poor (HR = 18.5, 95% CI = 3.30 to 103) health. Relationships between pain and mortality were mediated through lowered physical activity (P = .036).</p><p><strong>Conclusions: </strong>Clinically actionable factors associated with early mortality identify high-risk TCS in need of closer monitoring and targeted interventions. The significant relationship between neuropathic pain and mortality, mediated by low physical activity, is the first to our knowledge in TCS.</p>","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":"1797-1808"},"PeriodicalIF":7.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12415966/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143079192","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Yijian Fan, Rui Jin, Lenore Monterroza, Xiuju Liu, Chunzi Huang, Angelo Marra, Xiulei Mo, Haian Fu, Melissa Gilbert-Ross, Adam I Marcus, Rabindra Tirouvanziam, Yuan Liu, Frank Schneider, Wei Zhou
{"title":"Suppression of LKB1-mutant lung adenocarcinoma by natural killer cells from females.","authors":"Yijian Fan, Rui Jin, Lenore Monterroza, Xiuju Liu, Chunzi Huang, Angelo Marra, Xiulei Mo, Haian Fu, Melissa Gilbert-Ross, Adam I Marcus, Rabindra Tirouvanziam, Yuan Liu, Frank Schneider, Wei Zhou","doi":"10.1093/jnci/djaf138","DOIUrl":"10.1093/jnci/djaf138","url":null,"abstract":"<p><strong>Background: </strong>This study addressed the enigma of sex differences in smoking-related lung cancer, particularly focusing on the low LKB1 mutation frequency in female patients with lung adenocarcinoma.</p><p><strong>Methods: </strong>Sex bias was studied with a genetically engineered mouse model and various tail-vein injection models. Immune cells were analyzed by antibody-depletion study, flow cytometry, and immunofluorescence. The relevance of our findings to human disease was validated by evaluating various lung adenocarcinoma datasets. All statistical tests are 2-sided.</p><p><strong>Results: </strong>A statistically significant percentage of females are resistant to LKB1-mutant tumor formation in our models, reflecting this sex difference in humans. Natural killer (NK) cells were identified as a critical factor in this sex-biased response. This sex difference was observed primarily in LKB1-mutant lung adenocarcinoma, probably due to their low major histocompatibility complex class I level, making them the ideal target for NK cells through the missing-self recognition. Although females resistant to LKB1-mutant lung adenocarcinoma formation did not have enhancement of any specific NK subpopulation, our immunofluorescence analysis revealed high numbers of NKs in female lungs even with the presence of LKB1-mutant lung adenocarcinoma. Our gene set enrichment analysis of The Cancer Genome Atlas-lung adenocarcinoma dataset also showed that female LKB1-mutant lung adenocarcinoma patients have a stronger NK-mediated response after adjusting for other male-female differences using the LKB1 wild-type lung adenocarcinoma dataset.</p><p><strong>Conclusion: </strong>Females have a stronger NK-mediated response against LKB1-mutant lung adenocarcinoma, which was present in our mouse model and the human lung adenocarcinoma dataset. This study revealed a novel role of NK cells in suppressing LKB1-mutant lung adenocarcinoma in females, which should be assessed in the clinical setting in the future.</p>","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":"1858-1867"},"PeriodicalIF":7.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12415955/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144284382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"RE: Association of radiation-induced normal tissue toxicity with a high genetic risk for rheumatoid arthritis.","authors":"Qu Zheng, Bao-Qiang Dong, Yiyan Han","doi":"10.1093/jnci/djaf144","DOIUrl":"10.1093/jnci/djaf144","url":null,"abstract":"","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":"1946-1947"},"PeriodicalIF":7.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144293685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Farzana Y Zaman, Suzanne G Orchard, Galina Polekhina, Peter Gibbs, Wendy B Bernstein, Finlay Macrae, Jeanne Tie, Jeremy Millar, Lucy Gately, Luz María Rodríguez, Gijsberta J van Londen, Victoria Mar, Emma Hiscutt, Nikki Adler, Aaron Kent, Wee Loon Ong, Andrew Haydon, Erica Warner, Andrew T Chan, John Zalcberg
{"title":"Association of non-steroidal anti-inflammatory medications and aspirin with colorectal cancer incidence in older adults.","authors":"Farzana Y Zaman, Suzanne G Orchard, Galina Polekhina, Peter Gibbs, Wendy B Bernstein, Finlay Macrae, Jeanne Tie, Jeremy Millar, Lucy Gately, Luz María Rodríguez, Gijsberta J van Londen, Victoria Mar, Emma Hiscutt, Nikki Adler, Aaron Kent, Wee Loon Ong, Andrew Haydon, Erica Warner, Andrew T Chan, John Zalcberg","doi":"10.1093/jnci/djaf145","DOIUrl":"10.1093/jnci/djaf145","url":null,"abstract":"<p><strong>Background: </strong>The relationship between aspirin, and/or other non-steroidal anti-inflammatory drugs (NSAIDs), and colorectal cancer (CRC) risk in older adults is uncertain. This study investigated the association between non-aspirin NSAIDs (NA-NSAIDs) use, alone or combined with aspirin, on CRC incidence in older adults.</p><p><strong>Methods: </strong>This is a post hoc analysis of ASPirin in Reducing Events in the Elderly (ASPREE) randomized controlled trial data and its observational continuation, ASPREE-XT (median follow-up, 8.4 years [IQR: 7.2-9.6]). NA-NSAID exposure was ascertained by self-report and medical record review at baseline, for all ASPREE participants, and for Australian participants, via linkage to the Pharmaceutical Benefits Scheme (PBS). CRC was an adjudicated secondary endpoint of ASPREE. We investigated the association between NA-NSAID use alone, and in combination with randomized aspirin use, on the incidence of CRC in time-to-event analyses.</p><p><strong>Results: </strong>Of 19 114 ASPREE participants, 2713 (14%) reported NA-NSAID use at baseline. NA-NSAID use was associated with a reduced incidence of CRC (HRNA-NSAID use: Yes vs No = 0.74; 95% CI = 0.56 to 0.98). This association between NA-NSAIDs and CRC was not modified by aspirin (P-value for interaction term of 0.81). When assessing NA-NSAID use over 2 years post-randomization in Australian participants who consented to the use of PBS data (n = 13 725), a similar reduction in CRC risk was observed (HRHigh NA-NSAID use vs None = 0.52, 95% CI = 0.32 to 0.83).</p><p><strong>Conclusions: </strong>NA-NSAID use in Australian and American adults over the age of 70 years was associated with a reduced CRC incidence, which increased with increasing exposure. Aspirin did not modify the effect of NA-NSAIDs on CRC incidence.</p>","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":"1875-1882"},"PeriodicalIF":7.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12415954/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144293684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}